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ABSTRACT 
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are characterized by 
increased pulmonary and systemic inflammation and commonly caused by bacterial and/or viral 
infection. Little is known about the T-cell dysregulation in AECOPD that promotes these outcomes. 
CD39 is an ectonucleotidase able to hydrolyse adenosine triphosphate to create adenosine that may 
inhibit T-cell responses in patients with AECOPD. Here T-cell expression of CD39 measured by flow 
cytometry was higher in AECOPD patients than stable COPD patients or healthy controls. Higher 
expression of CD39 was associated with higher levels of plasma soluble tumor necrosis factor 
receptor but lower interferon-γ (IFNγ) levels in supernatants from staphylococcal enterotoxin-B 
stimulated peripheral blood mononuclear cells. This links increased expression of CD39 with 
systemic inflammation and impaired T-cell responses (e.g. IFNγ). The blockade of CD39 pathways 
may be a novel approach to the control of AECOPD, reducing the dependency on antibiotics. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is amongst the top five causes of global morbidity 
and mortality. COPD is characterized by chronic airway and systemic inflammation and so 
predisposes patients to ischemic heart disease, vascular disease, muscle wasting and cachexia [1, 2]. 
COPD patients may also experience acute exacerbations (AECOPD), commonly caused by infections 
[3]. AECOPD can accelerate the decline in lung function [4], but the associated immune 
dysregulation is not well understood. AECOPD may be an immune-deficient state reflecting an 
impaired T-helper type I (Th1) responses to infectious agents (e.g. decreased production of IFNγ) [5-
9]. There are several anti-inflammatory molecules, including CD39 that may be highly expressed in 
AECOPD that may inhibit IFNγ responses.  
 
CD39 is an ectonucleotidase which generates adenosine monophosphate (AMP) from adenosine 
triphosphate/adenosine diphosphate (ATP/ADP). CD73 (another ectonucleotidase) then converts 
AMP to adenosine, an anti-inflammatory molecule that can inhibit the function of CD4+ and CD8+ 
T-cells and natural killer cells [10]. CD39 is highly expressed by regulatory T-cells (Tregs) and is 
important for their immune-suppressive function [11, 12]. Inflammation usually results in the release 
of ATP that is converted to adenosine by Tregs via the CD39/CD73 pathway. The binding of 
adenosine to A2A receptors downregulates the activity of effector T-cells but promotes the expansion 
of Tregs and their suppression of effector T-cell proliferation [13]. 
 
Therefore, CD39 and CD73 are important in the regulation of immune responses by inhibiting the 
ATP-driven pro-inflammatory immune cell activity and promote an anti-inflammatory state mediated 
by adenosine [10]. Since AECOPD may be an immunodeficient state, we hypothesized that chronic 
inflammation induces the expression of CD39 that then inhibits protective effector T-cell responses 
(e.g. IFNγ production) against bacteria in AECOPD.   
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2. Material and methods 
2.1 Study subjects  
AECOPD patients (n=21) admitted to the Royal Perth Hospital Emergency Department (Western 
Australia) were recruited. Stable COPD (sCOPD) patients who were previous smokers (>15 pack-
years and ceased smoking >5 years earlier) from a dedicated Royal Perth Hospital COPD clinic 
(n=33) and healthy age-matched, non-smoking subjects with no clinical evidence of COPD were also 
included as controls (n=33). The diagnosis and severity of COPD was categorised by a respiratory 
physician according to the GOLD criteria (Stages 2-4). All patients had been treated with 
anticholinergic drugs, long-acting beta agonists and inhaled corticosteroids but none were receiving 
systemic corticosteroids or had diabetes, neuromuscular, allergic or rheumatological disease at the 
time of sampling. The study was approved by the Ethics Committee at the Royal Perth Hospital and 
all participants gave informed consent.  
 
2.2 Sample and data collection 
Peripheral blood mononuclear cells (PBMC) were isolated from blood collected in lithium heparin 
tubes by Ficoll gradient centrifugation and cryopreserved in 10% dimethyl sulfoxide/fetal calf serum. 
Plasma was stored at -80oC. Plasma levels of IL-6, C-reactive protein (CRP) and sTNFR were 
measured by ELISA (R&D Systems, Minneapolis, MN). Proportions of CD39+ T-cells were 
quantified by flow cytometry after staining PBMC with anti-CD3-APC-H7, CD4-V500, CD8-PerCP-
Cy5.5, CD39-FITC, CD28-PE-Cy7 and PD-1-APC antibodies (BD Biosciences, San Jose, CA). 
Intracytoplasmic staining was performed using the BD PharmingenTM FoxP3 buffer set and FoxP3-
PE antibody (BD Biosciences). 200,000 events were acquired using a BD FACSCanto II cytometer 
and analyses were done with FlowJo v5.7.2 software (Tree Star, Ashland, OR). Gating for T-cell 
subsets and expression of CD39 is shown in Figure 1. Concentrations of IFNγ, TNFα, IL-6, IL-10 
(BD Biosciences) and IL-17 (eBioscience, San Diego, CA) were measured by ELISA in supernatants 
from PBMC (2x106 cells/mL) cultured with SEB (1μg/mL; Sigma-Aldrich, St. Louis, MO) for 24hr. 
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2.3 Data Analysis 
Non-parametric Mann-Whitney tests were used to compare groups. Correlations were assessed using 
Spearman’s rank correlation coefficient. Statistical analyses were performed with Graphpad Prism 
5.04 software (La Jolla, CA). Statistically significant differences (p<0.05) are indicated in the figures 
and p=0.05-0.10 is noted as marking a trend.  
 
3. Results 
3.1 AECOPD patients exhibited systemic inflammation but decreased SEB-induced IFNγ 
production 
Stable COPD (sCOPD) and AECOPD patients had elevated plasma levels of CRP (p=0.004 & 
p<0.001, respectively), IL-6 (p=0.001 & p=0.003, resp.) and sTNFR (p=0.007 & p<0.001, resp.) 
when compared to healthy controls (Figure 2, A-C). AECOPD patients had marginally higher plasma 
CRP (p=0.07), IL-6 (p=0.09) and sTNFR (p=0.04) than sCOPD patients.  
 
Following stimulation with SEB, levels of IFNγ, TNFα and IL-6 was lower in PBMC from AECOPD 
patients than sCOPD patients (p=0.0001-0.002) and healthy controls (p=0.0004-0.005) (Figure 2, D-
F). The production of IL-17 and IL-10 was lower in AECOPD patients than controls (p=0.05 for both) 
and sCOPD patients (p=0.06 and p=0.002, respectively) (Figure 2G and 2H). Level of plasma sTNFR 
showed weak to moderate negative associations with the levels of IFNγ (r=-0.23, p=0.07), IL-6 (r=-
0.23, p=0.07), IL-17 (r=-0.31, p=0.04) and IL-10 (r=-0.32, p=0.02) in culture supernatants. 
 
3.2 Expression of CD39 on T-cells correlates directly with plasma sTNFR and inversely with 
IFNγ production by T-cells 
Proportions of circulating CD39+ CD4+ and CD8+ T-cells, Tregs (Foxp3+ CD4+ T-cells) and non-
Tregs (Foxp3- CD4+ T-cells) were higher in AECOPD patients than sCOPD patients (Figure 3A). 
Compared to healthy controls, AECOPD patients exhibited increased proportion of CD39+ CD8+ T-
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cells (p=0.008) and marginal higher proportion of CD39+ CD4+ T-cells (p=0.08). Furthermore, 
plasma sTNFR correlated directly with proportions of CD39+ CD4+ T-cells (r=0.25, p=0.048) and 
CD8+ T-cells (r=0.28, p=0.027). The proportion of CD39+ T-cells correlated inversely with the levels 
of IFNγ produced by SEB-stimulated PBMC (Figure 3, B-E), but not with levels of TNFα, IL-6, IL-




This study describes for the first time the expression of CD39 on circulating T-cell subsets in relation 
to systemic inflammation and cytokine responses of patients with stable COPD or AECOPD. Our 
data demonstrated that the proportion of CD39-expressing CD4+, CD8+, Foxp3+ (Tregs) and FoxP3- 
T-cells were increased in the circulation of AECOPD patients. This increase was associated with 
systemic inflammation as evidenced by a correlation with plasma levels of sTNFR. Furthermore, 
PBMC from AECOPD patients had impaired production of cytokines important for bacterial 
clearance such as IFNγ, TNFα, IL-6 and IL-17. Proportions of CD39+ T-cells correlated inversely 
with SEB-induced IFNγ responses. This is in line with the findings with other inflammatory 
conditions which support a role for the CD39 and associated purinergic signalling pathways in 
inhibiting immune responses during chronic inflammation. 
 
Increased numbers of CD39+ cells that may provide anti-inflammatory functions have been isolated 
in inflammatory sites such as joints of arthritic patients [14], bronchoalveolar lavage from COPD 
patients [15], and lamina propria of patients with Crohn’s disease [16]. Circulating antigen-reactive 
CD4+ T-cells expressing CD39 were also increased in patients with active rather than latent 
tuberculosis [17]. There is growing evidence to suggest that CD39 inhibits IFNγ production. Notably 
depletion of CD39+ Treg increased TB-specific antigen responses [18]. Furthermore, Bai et al 
demonstrated that CD39+ CD8+ T-cells inhibited IFNγ production by CD39- CD8+ T-cells from 
healthy control samples [16].  
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Increased expression of CD39 has also been associated with other markers of T-cell exhaustion or 
dysfunction. This includes increased expression of PD-1 paralleling the decreased expression of 
CD28 and production of IFNγ [19]. In our patient cohort, we correlated increased CD28null T-cells in 
COPD and AECOPD with CMV-IgG titres [20]. Here increased expression of CD39 correlated with 
the loss of CD28 expression on CD4+ T-cells (r=-0.245, p=0.047) and increased PD-1 expression 
(r=0.278, p=0.024). Within the Treg population, expression of CD39 also correlated with the 
expression of PD-1 (r=0.882, p=0.004). The data suggest that CD39 may promote immune exhaustion 
in patients with COPD and so contribute to the suppression of protective immune responses.  
 
Our results build on the work by Lazar et al (2015) showing increased expression of CD39 on cells 
from bronchoalveolar lavage fluid and sputum of ex-smoking COPD patients than smokers and non-
smoking controls [15]. They demonstrated that cigarette smoking induces the expression of CD39 on 
bronchoalveolar lavage cells and lung tissue, and proposed a compensatory upregulation of CD39 as 
a protective mechanism in cigarette smoke-induced lung damage. Our data suggests that the increased 
CD39 expression is not only limited to the lung environment but is also evident systemically, possibly 
as a compensatory response to chronic inflammation in COPD resulting in poorer T-cell responses. 
Blockade of CD39 may restore T-cell responses, but abrogation of CD39 in knockout mice promoted 
emphysema [15], and cigarette smoke can reduce CD39 expression in the lung, macrophages and 
vascular endothelial cells [21]. Therefore, further studies and refinements are required before CD39 
is accepted as an appropriate theraupeutic target,. 
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FIGURE LEGENDS 
Figure 1 – Gating strategies used to identify CD39+ T-cell subsets: (A) Singlets were gated based 
on the expression of forward scatter-area (FCS-A) and FCS-Height. (B) Dead cells were then 
excluded and (C) lymphocytes were gated based on the expression of side scatter (SSC)-A and FSC-
A. (D) CD4+ or (E) CD8+ T-cells were identified by co-expression of CD3 with CD4 or CD8 
respectively. (F) Co-expression of CD39 and Foxp3 from CD4+ T-cells. 
 
Figure 2 – Increased plasma biomarkers of inflammation but decreased production of IFNγ by 
PBMC in AECOPD patients. A) CRP, B) IL-6 and C) sTNFR in plasma and levels of (D) IFNγ, (E) 
TNFα, (F) IL-6, (G), IL-17 and (H) IL-10 in supernatants of PBMC+SEB cultures were measured by 
ELISA. ***p<0.001, **p<0.01, *p<0.05, Mann-Whitney t-test. 
 
Figure 3 – Frequencies of CD39 expressing T-cells were elevated in AECOPD patients and 
associate with decreased production of IFNγ in response to SEB. (A) Proportion of CD39+ cells 
(as a % of parent population). (B-E) Correlation of IFNγ level in supernatants with proportion of 
CD39-expressing T-cell subsets. ***p<0.001, **p<0.01, *p<0.05, Mann-Whitney t-test. 
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